



Ferinject®

 Vifor Pharma






Iron Deficiency Anemia-IDA

- IDA is the most common and widespread nutritional disorder in the world.
- It is the only nutrient deficiency also prevalent in industrial countries.
- Some disorders, such as IBD, are prone to develop IDA.
- 1/3 of the IBD's patients has reduced Hb.
- Every second patient is ID.


• [Kulnigg S et al. Am J Gastroenterol 2007;102:1](#)



Factors to IDA in IBD's patients




IDA-Symptoms



Fatigue, weakness and impaired physical function adversely affect the lives and well-being of your patients (Cancer)

Fatigue has a greater impact on the life of a cancer patient than pain¹



- ▶ In cancer patients, fatigue significantly impacts QoL^{2,3}
- ▶ 61% of cancer patients surveyed (n=419) said that fatigue had a more substantial effect on their daily lives than pain¹

Responses to the question:

(Patient) Which symptom do you think affects/affected your everyday life more, pain or fatigue?

(Oncologist) Which symptom do you think affects your patients' everyday life more, pain or fatigue?


1. [Vogelzang NJ et al. Semin Hemat 1997;34:4.](#)
2. [Cella D et al. Semin Oncol 1998;25:43.](#)
3. [Cella D. Cancer 2008;113\(6\):1480-8.](#)

Oral treatment



Up to 90% of oral iron is not absorbed

10% absorbed




 Vifor Pharma



Oral iron treatment



- Easy to administer & Low cost.
- Poor absorption from the gastrointestinal tract.
- Gastrointestinal side effects
 - constipation 35%
 - nausea 10%
 - vomiting 8%
 - diarrhea 6%
- Variable compliance.
- Interaction with medications.
- Interaction with food.
- Can't balanced continuance iron loose.



Charytan C et al. Nephron Clin Pract 2005; 100: c55-c62



The majority of patients require at least 1 g of utilizable iron


- ▶ Post-Partum:
 - [Van Wyck DB et al. Obstet Gynecol 2007;110:267:](#) 1,403 mg iron
 - [Breymann C et al. Int J Gynaecol Obstet 2008;101:67:](#) 1,347 mg iron
 - [Seid MH et al. Am J Obstet Gynecol 2008;199:435:](#) 1,504 mg iron
- ▶ Heavy Menstrual Bleeding:
 - [Van Wyck DB et al. Transfusion 2009;49:2719:](#) 1,568 mg iron
- ▶ Oncology:
 - [Tschechne B et al. DHGO Congress poster, Berlin 2010](#) 1,333 mg iron
 - I.V. iron other studies: 750–1,200 mg iron
- ▶ CKD:
 - [Qunibi WY et al. Nephrol Dial Transplant 2010 \(Epub ahead of print\):](#) 1,218 mg iron
- ▶ IBD:
 - [Kulnigg S et al. Am J Gastroenterol 2007;102:1:](#) 1,399 mg iron

IV Iron Therapy – What are we looking for?



- Safety & effectiveness
- Rapid correction of iron deficiency
- Low toxicity
- Low reactivity with molecules in blood and living cells
- No induction of oxidative stress
- Minimum repeated infusion


Ferinject® – Breakthrough next generation I.V. iron





FERINJECT


- Ferinject® is a stable complex free of dextran
Designed to overcome current I.V. iron limitations
- Ferric carboxymaltose - FCM
- Low immunogenic potential and iron-induced toxicity
- Well documented safety and tolerability profile
- Single dose up to 1000 mg iron in 15 minutes only
- No test dose required






FERINJECT


- Unique carbohydrate shell
- Highly stable type I iron complex
- Dextran-free
- PH 5–7
- Physiological osmolarity
- Rapid and selective delivery from plasma to RES of the liver, spleen and bone marrow.



Metabolism and toxicity of an ICC




Ferinject[®] provides a more rapid correction of iron deficiency compared with oral iron (IBD)




Ferinject[®] provides a more rapid correction of iron deficiency compared with oral iron (HMB)




Significantly more patients achieving a Hb >12g/dl



Significantly more patients with a Hb increase of ≥3g/dl



Significantly higher serum ferritin values




Ferinject[®] was **significantly superior** to oral iron in normalizing haemoglobin and replenishment of iron stores

[Van Wyck DB et al. Transfusion 2009;49:2719](#)

 Vifor Pharma



Only 1–2 injections of Ferinject® needed in > 90% of patients¹




Clinical Profile: Anaemia in postpartum

¹ van Wyck DB, 2007

Ferinject® has a good and well documented safety and tolerability profile



Well tolerated even at single doses up to 1,000 mg iron



Ferinject® cumulative doses $\geq 1,000$ mg iron in 88% of patients (n = 1,736)


[Qunibi W. ERA-EDTA Congress poster 2008, Sweden](#)
[Lyseng-Williamson KA & Keating GM. *Drugs*. 2009;69\(6\):739](#)



Ferinject® offers a simple and cost-effective treatment option for both physicians and patients



- ▶ *The associated savings with Ferinject® are that significant that it becomes the most economically viable option in three different therapeutic areas. These economic benefits are substantiated through the most optimal cost-neutral price and through the lowest administration costs in treating patients with iron deficiency*
- ▶ **Costs of administration – Ferinject® corresponding to 1,000mg iron is the lowest**



Szucs TD et al. Health-economic impact University of Zurich, Switzerland.



Ferinject® – Minimal intervention, maximum impact



High dose drip infusions

single dose up to 1000 mg iron
in 15 minutes only
no test dose required

500 mg (10 ml)
concentration 50 mg iron/ml



 Vifor Pharma







Thank you